TCTR20180828014尚未招募1 期
Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Gabapentin 300 mg Capsules and Reference Product (NEURONTINâ„¢ 300 mg) in Healthy Thai Volunteers under Fasting Conditions
International Bio Service0 个研究点目标入组 30 人开始时间: 2018年8月28日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •1.Healthy Thai male or female subjects between the ages of 18 to 55 years.
- •2.Body mass index between 18.0 to 30.0 kg/m2.
- •3.Normal laboratory values, including vital signs and physical examination, for all parameters in clinical laboratory tests at screening.
- •Any abnormalities from the normal or reference range will be carefully considered clinically relevant by the physician as individual cases, documented in study files prior to enrolling the subject in this study.
- •4.Non-pregnant woman (negative pregnancy test) and not currently breast feeding.
- •5.Female subjects abstain from either hormonal methods of contraception (including oral or transdermal contraceptives, injectable progesterone, progestin subdermal implants, progesterone-releasing IUDs, postcoital contraceptive methods) or hormone replacement therapy for at least 28 days prior to admission in Period 1. Injectable contraceptives e.g. Depo-Provera® will be discontinued at least 6 months prior to admission in Period 1. Subjects agree to use acceptable non-hormonal contraceptive methods such as condom, diaphragm, foams, jellies, or abstinence for at least 14 days prior to admission in Period 1 until 7 days after the end of study in Period 2. Female subjects of non-childbearing potential must meet at least one of the following criteria prior to admission in Period 1:
- •-Postmenopausal for at least 1 year or
- •-Surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy) at least 6 months
- •6.Male subjects who are willing or able to use effective contraceptive e.g. condom or abstinence after admission in Period 1 until 7 days after the end of study in Period 2.
- •7.Have voluntarily given written informed consent (signed and dated) by the subject prior to participating in this study.
排除标准
- •1.History of allergic reaction or hypersensitivity to gabapentin or any of the components of the product
- •2.History or evidence of clinically significant renal, hepatic, gastrointestinal, hematological, endocrine (e.g. thyroid), pulmonary or respiratory, cardiovascular, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) or any significant ongoing chronic medical illness
- •3.History or evidence of all types of epilepsy, seizure or neuropathic pain
- •4.History or evidence of hematologic disorder such as ecchymosis, anemia
- •5.History or evidence of behavioral abnormalities e.g. psychotic symptoms, irritability, aggressive behavior or depress
- •6.History of suicidal thoughts, behavior or suicide attempts in the past 30 days prior to screening or during enrollment in the study
- •7.History or evidence of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption
- •8.History of problems with swallowing capsule or capsule
- •9.History of sensitivity to heparin or heparin-induced thrombocytopenia
- •10.Any condition possibly affecting drug absorption e.g. gastrectomy, enterectomy, gastritis or duodenal or gastric ulceration other than appendectomy
- •11.History of preceding diarrhea within 24 hours prior to admission in each period
- •12.History or evidence of drug addict or investigation with urine sample shows a positive test for drug of abuse (morphine, marijuana or methamphetamine)
- •13.12-lead ECG demonstrating QTc >450 msec, a QRS interval >120 msec or with an abnormality considered clinically significant at screening. If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG will be repeated two more times and the average of the three QTc or QRS values will be used to determine the subject’s eligibility
- •14.Investigation with blood sample shows positive test for HBsAg.
- •15.Abnormal liver function, ≥ 1.5 times of upper normal limit of reference range for ALT, AST or bilirubin levels at screening laboratory test
- •16.History or evidence of habitual use of tobacco or nicotine containing products and cannot abstain for at least 7 days prior to admission and continued until last sample collection in each study period
- •17.History or evidence of alcoholism, regular alcohol consumption or alcohol-containing products and cannot abstain for at least 7 days prior to admission and continued until last sample collection in each study period
- •18.History or evidence of habitual consume of tea, coffee, xanthine or caffeine containing products and cannot abstain for at least 7 days prior to admission and continued until last sample collection in each study period
- •19.Consume or drink juice of grapefruit or orange or pomelo or its supplement/containing products and cannot abstain for at least 7 days prior to admission and continued until last sample collection in each study period
- •20.Use of prescription or nonprescription drugs (e.g. antacid, paracetamol, erythromycin, ketoconazole, etc.), herbal medications or supplements (e.g. St John’s wort), vitamins or mineral (e.g. iron) or dietary supplements within 14 days prior to admission in Period 1 or during enrollment
- •21.Participated in other clinical trials within 90 days prior to admission in Period 1 (except for the subjects who drop out
研究者
相似试验
尚未招募
1 期
A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Alfuzosin Hydrochloride 10 mg Prolongedrelease Tablets and Reference Product Xatral® XL 10 mg in Healthy Thai Male Volunteers under Fasting Conditions-Pilot StudyHealthy Thai Male VolunteersTCTR20180222003International Bio Service8
尚未招募
1 期
A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Desvenlafaxine 50 mg Extended-release Tablets and Reference Product (Pristiqâ„¢ 50 mg) in Healthy Thai Volunteers under Fasting Conditions - Pilot StudyHealthy Thai VolunteersTCTR20180924002International Bio Service10
尚未招募
1 期
A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Olanzapine 5 mg Orodispersible Tablets (5 MG TABLET)) and Reference Product (Zyprexa® Zydis®) in Healthy Thai Volunteers under Fasting ConditionsHealthy volunteersTCTR20180103001International Bio Service30
尚未招募
1 期
A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets and Reference Product, Xatral® XL 10 mg, in Healthy Thai Male Volunteers under Fed and Fasting ConditionsHealthy Thai Male VolunteersTCTR20181115002International Bio Service42
尚未招募
1 期
A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Gliclazide 60 mg Modified Release Tablets and Reference Product (DIAMICRON® MR 60mg) in Healthy Thai Volunteers under Fasting Conditions - Pilot StudyHealthy Thai VolunteersTCTR20180517004International Bio Service8